On January 15, 2021, Chen, Xin; Yang, Xi; Mao, Fei; Wei, Jinlian; Xu, Yixiang; Li, Baoli; Zhu, Jin; Ni, Shuaishuai; Jia, Lijun; Li, Jian published an article.Quality Control of 4-(Bromomethyl)-1,1′-biphenyl The title of the article was Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo. And the article contained the following:
In this study, I [R = H, aminopropane(CO), aminocyclopropane(CO),..etc]. were designed and synthesized based on lead compound CDC to improve the neddylation inhibition and anticancer efficacy. Optimal benzimidazole-derived I [R = (2,4-dichlorophenyl)-1-ethylamino(CO)] displayed superior neddylation inhibition in enzyme assay compared to CDC (IC50 = 5.51μM vs 16.43μM), along with promising target inhibitory activity and killing selectivity in cancer cell. The results of cellular mechanism research combined with tumor growth suppression in human lung cancer cell A549 in vivo, accompanied with docking model, revealed that I [R = (2,4-dichlorophenyl)-1-ethylamino(CO)] had the potential to be developed as a promising neddylation inhibitor for anticancer therapy. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Quality Control of 4-(Bromomethyl)-1,1′-biphenyl
The Article related to benzimidazolyl methylbiphenylyl tetrazole preparation antitumor agent sar enzyme inhibitor, anticancer, benzimidazole-derived inhibitor, neddylation, cullin1-nedd8, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Quality Control of 4-(Bromomethyl)-1,1′-biphenyl
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary